Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Argus Health
Farmers Insurance
Merck
Deloitte
Cipla
Fish and Richardson
QuintilesIMS
Cantor Fitzgerald
Federal Trade Commission

Generated: October 20, 2017

DrugPatentWatch Database Preview

Taro Company Profile

« Back to Dashboard

What is the competitive landscape for TARO, and what generic alternatives to TARO drugs are available?

TARO has two hundred and five approved drugs.

There are ten US patents protecting TARO drugs. There are three tentative approvals on TARO drugs.

There are sixty-two patent family members on TARO drugs in seventeen countries and sixty-nine supplementary protection certificates in eleven countries.

Summary for Applicant: Taro

International Patents:62
US Patents:10
Tradenames:105
Ingredients:89
NDAs:205
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Taro
ENALAPRIL MALEATE
enalapril maleate
TABLET;ORAL075657-004Jan 23, 2001ABRXNoNo► Subscribe► Subscribe► Subscribe
Taro
TOPICORT
desoximetasone
GEL;TOPICAL074904-001Jul 14, 1998ABRXNoYes► Subscribe► Subscribe► Subscribe
Taro
BETAMETHASONE DIPROPIONATE
betamethasone dipropionate
CREAM;TOPICAL073552-001Apr 30, 1992ABRXNoNo► Subscribe► Subscribe► Subscribe
Taro Pharm
LORATADINE
loratadine
SYRUP;ORAL201865-001Jul 31, 2015OTCNoNo► Subscribe► Subscribe► Subscribe
Taro
ACETAZOLAMIDE
acetazolamide
TABLET;ORAL040195-001May 28, 1997ABRXNoNo► Subscribe► Subscribe► Subscribe
Taro
CARVEDILOL
carvedilol
TABLET;ORAL077780-002Sep 5, 2007ABRXNoNo► Subscribe► Subscribe► Subscribe
Taro
DICLOFENAC SODIUM
diclofenac sodium
GEL;TOPICAL206298-001Apr 28, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Taro
NITROFURAZONE
nitrofurazone
OINTMENT;TOPICAL086156-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Taro Pharm
BETAMETHASONE VALERATE
betamethasone valerate
AEROSOL, FOAM;TOPICAL208204-001May 24, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Taro
PHENYTOIN
phenytoin
SUSPENSION;ORAL040521-001Mar 8, 2004ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Taro

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Taro
FLO-PRED
prednisolone acetate
SUSPENSION;ORAL022067-001Jan 17, 2008► Subscribe► Subscribe
Taro
FLO-PRED
prednisolone acetate
SUSPENSION;ORAL022067-002Jan 17, 2008► Subscribe► Subscribe
Taro
FLO-PRED
prednisolone acetate
SUSPENSION;ORAL022067-001Jan 17, 2008► Subscribe► Subscribe
Taro Pharms
PLIAGLIS
lidocaine; tetracaine
CREAM;TOPICAL021717-001Jun 29, 2006► Subscribe► Subscribe
Taro
FLO-PRED
prednisolone acetate
SUSPENSION;ORAL022067-002Jan 17, 2008► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for TARO drugs

Drugname Dosage Strength Tradename Submissiondate
desoximetasone
Topical Spray0.25%
TOPICORT
12/18/2013
malathion
Topical Lotion0.5%
OVIDE
3/16/2011

Premature patent expirations for TARO

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
► Subscribe ► Subscribe

Non-Orange Book Patents for Taro

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,039,657Process for preparing malathion for pharmaceutical use► Subscribe
5,886,038 Composition and method for treatment of psoriasis► Subscribe
8,206,727Oral suspension of prednisolone acetate► Subscribe
8,461,139Oral suspension of prednisolone acetate► Subscribe
8,536,155Process for preparing malathion for pharmaceutical use► Subscribe
6,355,258 Method for formulating spill resistant pharmaceutical compositions in semi-solid form► Subscribe
8,957,238Process for preparing malathion for pharmaceutical use► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Taro Drugs

Country Document Number Estimated Expiration
European Patent Office1909798► Subscribe
Canada2612578► Subscribe
Japan5474347► Subscribe
European Patent Office2630951► Subscribe
Japan2013032405► Subscribe
Austria345757► Subscribe
Japan2007126462► Subscribe
European Patent Office1082103► Subscribe
Canada2333405► Subscribe
Japan2012246315► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Taro Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0008Belgium► SubscribePRODUCT NAME: FOSPHENYTOINUM DINATRICUM; REGISTRATION NO/DATE: 19 IS 102 F12 19980901; FIRST REGISTRATION: GB PL00019/1057 19980204
C/GB11/054United Kingdom► SubscribePRODUCT NAME: BROMFENAC 2-AMINO-3-(4-BROMOBENZOYL)PHENYLACETIC ACID OR A PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF OR A HYDRATE THEREOF; REGISTERED: UK EU/1/11/692/001 20110523
01C/045Belgium► SubscribePRODUCT NAME: DICHLORHYDRATE DE LEVOCETIRIZINE; NAT RER. NO/DATE: 194 IS 90 F3 20011022; FIRST REG.: DE 49903.00.00 20010103
00085Netherlands► SubscribePRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103
00028Netherlands► SubscribePRODUCT NAME: LEVETIRACETAM; REGISTRATION NO/DATE: EU/1/00/146/001 - EU/1/00/146/026 20000929
C/GB99/003United Kingdom► SubscribePRODUCT NAME: IMIQUIMOD; REGISTERED: UK EU/1/98/080/001 19980918
C0008Belgium► SubscribePRODUCT NAME: RISPERIDONE; NAT REG.: 2 S 414 F 3 19940527; FIRST REG.: GB 0242/0186 19921208
C0052France► SubscribePRODUCT NAME: SUGAMMADEX SODIUM; REGISTRATION NO/DATE: EU/1/08/466/001-002 20080725
C/GB10/012United Kingdom► SubscribePRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112
C0055France► SubscribePRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: 434323 20130220
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
US Army
McKesson
Express Scripts
US Department of Justice
Healthtrust
Baxter
Julphar
Accenture
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot